A phase 1 dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL228 administered intravenously to subjects with chronic myeloid leukemia (CML) or Philadelphia-chromosome-positive acute lymphocytic leukemia (Ph+ALL).
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2015
At a glance
- Drugs XL 228 (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 04 Apr 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Apr 2011 Planned End Date changed from 1 May 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 02 Mar 2010 Planned end date changed from 1 Apr 2009 to 1 May 2010 as reported by ClinicalTrials.gov record.